Home › Trials › NCT05590702

Observational study of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma in France

French Observational Study of Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma in Real-World Settings

Observational French Innovative Leukemia Organisation · NCT05590702

This study is looking to gather information on how patients with chronic lymphocytic leukemia or small lymphocytic lymphoma in France are being treated and managed, especially with new therapies and tests.

Quick facts

Study typeObservational
Enrollment1000 (estimated)
Ages18 Years and up
SexAll
SponsorFrench Innovative Leukemia Organisation Academic / other
Drugs / interventionsimmunotherapy, rituximab, ibrutinib, cyclophosphamide, fludarabine
Locations57 sites (Amiens and 56 other locations)
Trial IDNCT05590702 on ClinicalTrials.gov

What this trial studies

This observational study aims to gather real-world data on patients diagnosed with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) in France. It will assess the management and treatment strategies employed for these patients, particularly in light of recent advancements in targeted therapies and genetic evaluations. The study will include patients aged 18 and older who require a therapeutic strategy, whether they are newly diagnosed or previously treated. Data will be collected from multiple centers across France to provide a comprehensive overview of current practices and outcomes.

Who should consider this trial

Good fit: Ideal candidates for this study are adults aged 18 and older diagnosed with CLL or SLL who require a therapeutic strategy.

Not a fit: Patients who do not have CLL or SLL or those who are not requiring therapy for their condition may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could enhance understanding of CLL and SLL management, leading to improved treatment strategies and patient outcomes.

How similar studies have performed: Other studies have successfully utilized observational approaches to gather data on CLL and SLL, indicating that this methodology is both valid and valuable.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Age ≥ 18-year old
* CLL or SLL requiring a therapeutic strategy according to iwCLL criteria or investigator evaluation
* Patient requiring therapy for immune events (autoimmune Thrombocytopenia and autoimmune hemolytic anemia) are eligible
* Patients who have been informed verbally and in writing about this study, and who do not object to their data being electronically processed or subjected to data quality control
* All consecutive patients for whom a discussion in the setting of local or regional multidisciplinary collegial meeting (in french : réunion de concertation pluridisciplinaire / RCP) has retained the need for starting a therapeutic strategy (curative or palliative)
* Patients with untreated or previously treated CLL/SLL are both eligible
* Patients enrolled in a clinical trial can be included in this non-interventional cohort study
* Patients requiring therapy for CLL/SLL-associated immune events only are also eligible

Exclusion Criteria:

* Patients with no need of therapy
* Patients with asymptomatic Binet A CLL
* Patient with Richter's syndrome at inclusion
* Patient requiring immunoglobulin substitution (with no need of a more specific therapy)

Where this trial is running

Amiens and 56 other locations

+7 more sites — see ClinicalTrials.gov for the full list.

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions CLL/SLL
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.